List view / Grid view
The ever-increasing pressure to turn bench-top discoveries into new therapies has led to the re-purposing of embryonic stem cell lines, originally intended for basic research, for clinical applications...
Flow cytometry has become a widely used technology in life science research. It is also essential for many pharma and biotechnology companies due to its proficiency in identifying biomarkers, developing biopharmaceuticals, and assessing the efficiency of new pharmacological protocols...
The multiplex and high-throughput capabilities of next-generation sequencing (NGS) allow researchers to study an immense number of DNA/RNA molecules per run, bringing opportunities to study biological or clinical research questions that could not be addressed before...
The Wellcome Trust Sanger Institute's Kim Judge explains how Next Generation Sequencing forms a crucial part of the scientist’s toolkit and makes a valuable contribution to the field of drug discovery...
Pushpanathan Muthuirulan & Pooja Sharma explain how high-throughput next-generation sequencing (NGS) technologies are revolutionising our ability to characterise infectious diseases at genomic, transcriptomic and epigenetic levels...
Next-generation sequencing (NGS) has greatly increased our understanding of biological phenomena and human disease. In particular, single-cell sequencing is one of the fastest-growing applications...
Next-generation sequencing is a crucial part of the scientist's toolkit. This in-depth focus compares the strengths and weaknesses of a range of NGS technologies and examines the benefits and challenges of using it in infectious disease diagnosis...
Using next-generation sequencing techniques enables pharmaceutical companies to explore the molecular landscape of disease initiation and progression with unprecedented clarity. Dr Sam Rulli, Product Manager at QIAGEN, provides his insight into the major challenges researchers face...
The power of single-cell sequencing and its application in the field of oncology remains a top opportunity for discoveries that could have a huge impact on improving human health worldwide. However, barriers remain before those studies can be furthered...
The development of technology that can ‘see’ inside our bodies is one of the great achievements of modern medicine.1 For over 100 years, doctors have used imaging methods for this very reason to help guide patient care. Initially, two-dimensional x-ray pictures of bones and chests were used to help diagnose…
Mass spectrometry imaging allows direct measurement of the molecular composition of a sample. It can be used to image the spatial distribution of exogenous drugs and endogenous metabolites simultaneously over the surface of tissue sections or small biopsy, allowing new insights into both compound efficacy and safety during drug discovery.
The automated imaging and high-content imaging (HCI) markets are experiencing a widening dichotomy of users’ needs. Diverse hardware and software solutions are needed to bridge this divide...
This In-Depth Focus explores current uses and future development in mass spectrometry imaging for bringing new drugs to market...
Assay robustness tends to be the favoured descriptor when a particular assay can cope with minute changes in the sample, equipment, or operator. The more robust an assay, the more predictive data it ultimately yields. The industry’s greatest challenge for assay development has always been using those robust assays to…
This in-depth focus looks at improving assay techniques to produce more detailed results using crystallography. It also covers some aspects of high-content screening assay development that are critical to successful implementation...
